Merit Medical Q3 revenue rises 8.4% to $416M

Q: How did MMSI perform in the third quarter of 2026?

MMSI reported third-quarter revenue of $416.244 million, up 8.4% year over year, and GAAP net income of $42.311 million, compared with $27.755 million a year earlier. Diluted EPS was $0.70 versus $0.46. Non-GAAP EPS was $1.12 versus $0.92.

Q: What is MMSI's updated 2026 financial guidance?

Merit updated full-year 2026 revenue guidance to $1.635 billion to $1.642 billion and non-GAAP EPS guidance to $4.33 to $4.37. Prior ranges were $1.631 billion to $1.643 billion and $4.25 to $4.35, respectively. The outlook is stated absent potential impacts from later trade actions, material acquisitions, non-recurring transactions, and other factors beyond current expectations.

Q: How did MMSI structure its Solo Pace acquisition, and what is the projected impact?

Merit paid approximately $45 million on October 13, 2026, to acquire Solo Pace’s remaining outstanding equity. Merit previously owned approximately 18% and had paid a total of $5 million under earlier agreements that included an option tied to commercialization milestones and exclusive distribution rights upon commercialization. The acquisition is projected to be slightly accretive to non-GAAP earnings and slightly dilutive to GAAP earnings in 2027.

The updated full-year outlook sets 2026 revenue at $1.635 billion to $1.642 billion and non-GAAP EPS at $4.33 to $4.37.

Filing Impact

(High)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Merit Medical Systems, Inc. (MMSI) reported third-quarter 2026 revenue of $416.244 million, up 8.4% year over year. GAAP net income was $42.311 million, compared with $27.755 million a year earlier, and diluted EPS was $0.70 versus $0.46. Non-GAAP operating income and non-GAAP EPS increased 17% and 22%, respectively. Organic constant-currency revenue growth, excluding the strategic divestiture, was 9%.

Merit updated full-year 2026 guidance to revenue of $1.635 billion to $1.642 billion and non-GAAP EPS of $4.33 to $4.37. The outlook is stated absent potential impacts from later trade actions, material acquisitions, non-recurring transactions, and other factors beyond current expectations. Merit paid approximately $45 million on October 13, 2026, for Solo Pace’s remaining equity. The acquisition is projected to be slightly accretive to non-GAAP net income and EPS in 2027, slightly dilutive to GAAP net income and EPS in 2027, and accretive thereafter. Nine-month operating cash flow was $175.230 million, compared with $198.861 million in 2025.

3 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance works How Sentiment works

0 major · 1 point

How the balance works

Positive

Moderate pointThird-quarter revenue increased 8.4% to $416.244 million.
Moderate pointGAAP net income increased to $42.311 million from $27.755 million.
Moderate pointNon-GAAP operating income rose 17%; non-GAAP EPS rose 22% year over year.

Negative

Moderate pointNine-month operating cash flow declined to $175.230 million from $198.861 million.

Insights

Analyzing...

8-K Event Classification

3 items: 2.02, 7.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Third-quarter revenue: $416.244 million GAAP net income: $42.311 million GAAP diluted EPS: $0.70 per share +5 more

8 metrics

Third-quarter revenue $416.244 million Three months ended September 30, 2026; up 8.4% year over year

GAAP net income $42.311 million Three months ended September 30, 2026; compared with $27.755 million in 2025

GAAP diluted EPS $0.70 per share Three months ended September 30, 2026; compared with $0.46 in 2025

Non-GAAP operating income $88.536 million Three months ended September 30, 2026; increased 17% year over year

Non-GAAP EPS $1.12 per share Three months ended September 30, 2026; increased 22% year over year

2026 revenue guidance $1.635 billion to $1.642 billion Updated full-year guidance

2026 non-GAAP EPS guidance $4.33 to $4.37 per share Updated full-year guidance

Operating cash flow $175.230 million Nine months ended September 30, 2026; compared with $198.861 million in 2025

Key Terms

constant currency revenue, organic, if-converted method, capped call, free cash flow

4 terms

constant currency revenue, organic financial

"Merit’s constant currency revenue, organic, is defined"

if-converted method financial

"calculated using the if-converted method"

An accounting rule used when calculating diluted earnings per share that imagines what would happen if all convertible securities—like convertible bonds, preferred shares, or options—had already been turned into common stock. It adjusts the company’s reported profit per share downward to show how earnings would be shared if ownership were spread across a larger number of shares, similar to checking how a pie’s slice size changes if more people join the table. This matters to investors because it reveals a more conservative view of each share’s claim on profits and potential future ownership dilution.

capped call financial

"offsetting impacts of the capped call"

A capped call is a financial strategy that gives investors the right to buy shares at a set price, known as the strike price, but limits the maximum profit they can make from that gain. Think of it as a sales agreement where you can purchase something at a fixed price, but there's a cap on how much extra you can earn if the item's value rises significantly. This helps investors protect themselves from unlimited upside risk while still participating in potential gains.

free cash flow financial

"Free cash flow is defined as cash flow from operations"

Free cash flow is the amount of money a company has left over after paying all its expenses and investing in its business, like buying equipment or updating facilities. It shows how much cash is available to reward shareholders, pay down debt, or save for future growth. This helps investors understand if a company is financially healthy and able to grow.

Earnings Snapshot

Net sales: $416.244 million · Guidance included

Three months ended September 30, 2026

Net sales $416.244 million 8.4% year over year

GAAP net income $42.311 million compared with $27.755 million

GAAP diluted EPS $0.70 per share compared with $0.46 per share

Non-GAAP operating income $88.536 million 17% year over year

Non-GAAP EPS $1.12 per share 22% year over year

Guidance

Updated full-year 2026 revenue guidance is $1.635 billion to $1.642 billion; updated non-GAAP EPS guidance is $4.33 to $4.37 per share.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How did MMSI perform in the third quarter of 2026?

MMSI reported third-quarter revenue of $416.244 million, up 8.4% year over year, and GAAP net income of $42.311 million, compared with $27.755 million a year earlier. Diluted EPS was $0.70 versus $0.46. Non-GAAP EPS was $1.12 versus $0.92.

What is MMSI's updated 2026 financial guidance?

Merit updated full-year 2026 revenue guidance to $1.635 billion to $1.642 billion and non-GAAP EPS guidance to $4.33 to $4.37. Prior ranges were $1.631 billion to $1.643 billion and $4.25 to $4.35, respectively. The outlook is stated absent potential impacts from later trade actions, material acquisitions, non-recurring transactions, and other factors beyond current expectations.

How did MMSI structure its Solo Pace acquisition, and what is the projected impact?

Merit paid approximately $45 million on October 13, 2026, to acquire Solo Pace’s remaining outstanding equity. Merit previously owned approximately 18% and had paid a total of $5 million under earlier agreements that included an option tied to commercialization milestones and exclusive distribution rights upon commercialization. The acquisition is projected to be slightly accretive to non-GAAP earnings and slightly dilutive to GAAP earnings in 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/29/2026 - 04:08 PM EDT Accepted by SEC EDGAR 10/29/2026 - 04:07 PM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): October 29, 2026

Merit Medical Systems, Inc.

(Exact name of registrant as specified in its charter)


Utah	0-18592	87-0447695
(State or other jurisdiction of	(Commission	(I.R.S. Employer
incorporation or organization)	File Number)	Identification No.)


1600 West Merit Parkway
South Jordan, Utah		84095
(Address of principal executive offices)		(Zip Code)

(801) 253-1600

(Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, no par value		MMSI		NASDAQ Global Select Market System

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On October 29, 2026, Merit Medical Systems, Inc. (“Merit”) issued a press release (the “Earnings Press Release”) announcing its operating and financial results for the quarter ended September 30, 2026. A copy of the Earnings Press Release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.

Item 7.01. Regulation FD Disclosure.

On October 29, 2026, Merit is conducting a conference call to discuss its operating and financial results for the quarter ended September 30, 2026. A live webcast and conference call presentation will also be available for the conference call at merit.com. A copy of the conference call presentation is furnished as Exhibit 99.2 to this report and incorporated herein by reference.

Additionally, on October 29, 2026, Merit issued a press release (the “Acquisition Press Release”) announcing its acquisition of Solo Pace, Inc. (“Solo Pace”) on October 13, 2026 pursuant to a Stock Purchase Agreement wherein Merit paid cash of approximately $45 million to acquire the outstanding equity interests of Solo Pace. A copy of the Acquisition Press Release is furnished as Exhibit 99.3 to this report and incorporated herein by reference.

The information contained in Item 2.02 and Item 7.01 of this report (including the exhibits attached hereto) is furnished pursuant to General Instruction B.2. of Form 8-K and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by Merit under the Securities Act of 1933, as amended, or the Exchange Act.

In addition to disclosing results that are determined in accordance with Generally Accepted Accounting Principles (“GAAP”), Merit is disclosing non-GAAP financial information in both the press release announcing its operating and financial results and the conference call presentation. Reconciliations of certain of these non-GAAP financial measures to the comparable GAAP financial measures are included in the press release and conference call presentation attached as Exhibit 99.1 and 99.2 to this report, respectively. Merit does not provide guidance for GAAP reported financial measures (other than revenue) or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures (other than revenue) because Merit is unable to predict with reasonable certainty the financial impact of items such as expenses related to acquisitions or other extraordinary transactions, non-cash expenses related to amortization or write-off of previously acquired tangible and intangible assets, certain severance expenses, performance-based stock compensation expenses, expenses resulting from non-ordinary course litigation or administrative proceedings and resulting settlements, governmental proceedings, and changes in governmental or industry regulations. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For the same reasons, Merit is unable to address the significance of the unavailable information, which could be material to future results. Specifically, Merit is not, without unreasonable effort, able to reasonably predict the amount and impact of these items, and Merit believes inclusion of the most directly comparable GAAP financial measure, and a reconciliation of these forward-looking non-GAAP figures to their GAAP counterparts, could be confusing to investors or cause undue reliance.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits


EXHIBIT NUMBER		DESCRIPTION

99.1		Press Release, dated October 29, 2026, entitled “Merit Medical Reports Third Quarter 2026 Results: Delivers 9% Organic Constant Currency Revenue Growth and Raises Full-Year 2026 Guidance” including unaudited financial information
99.2		Conference Call Presentation
99.3		Press Release, dated October 29, 2026, entitled “Merit Medical Acquires Solo Pace, Inc., Expanding Its Cardiac Therapies Platform with Innovative TAVR Pacing Technology”
104		The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MERIT MEDICAL SYSTEMS, INC.


Date: October 29, 2026	By:	/s/ Brian G. Lloyd
		Brian G. Lloyd
		Chief Legal Officer and Corporate Secretary

Exhibit 99.1


	Contacts:
	PR/Media Inquiries: Sarah Comstock Merit Medical	Investor Inquiries: Mike Piccinino, CFA, IRC ICR Healthcare
	+1-801-432-2864	+1-443-213-0509
	sarah.comstock@merit.com	mike.piccinino@icrhealthcare.com

FOR IMMEDIATE RELEASE

MERIT MEDICAL REPORTS THIRD QUARTER 2026 RESULTS: DELIVERS 9% ORGANIC CONSTANT CURRENCY REVENUE GROWTH AND RAISES FULL-YEAR 2026 GUIDANCE

Financial Highlights†

●

Reported revenue of $416.2 million, up 8.4%

●

Constant currency revenue* and constant currency revenue, organic* up 8% and up 9%, respectively

●

GAAP operating margin of 14.1%, compared to 11.1% in prior year period

●

Non-GAAP operating margin* of 21.3%, compared to 19.7% in prior year period

●

GAAP EPS $0.70, up 51%

●

Non-GAAP EPS* $1.12, up 22%

●

Cash flow from operations of $175.2 million year-to-date

●

Free cash flow* generation of $129.5 million year-to-date

† Comparisons above are calculated for the current quarter compared with the third quarter of 2025, unless otherwise specified. Amounts stated in this release are rounded, while percentages are calculated from the underlying amounts.

* Constant currency revenue; constant currency revenue, organic; non-GAAP gross profit and margin; non-GAAP operating income and margin; non-GAAP net income; non-GAAP EPS; and free cash flow figures (used here and below) are non-GAAP financial measures. A reconciliation of these financial measures to their most directly comparable GAAP financial measures is included under the heading “Non-GAAP Financial Measures” below.

SOUTH JORDAN, Utah, October 29, 2026 -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced financial results for the three and nine-month periods ended September 30, 2026.

“Merit delivered third quarter financial results that exceeded the high end of our expectations, driven primarily by 9% organic, constant currency revenue growth, excluding the impact of a strategic divestiture,” said Martha G. Aronson, Merit’s President and CEO. “We experienced strong revenue growth trends in the U.S. and better-than-expected demand for Merit’s products across both our Foundational and our Therapeutic platforms. We also delivered strong growth in both our non-GAAP operating profit and our non-GAAP earnings per share, which increased 17% and 22%, respectively, year-over-year.” Ms. Aronson

continued: “We have raised our 2026 revenue and non-GAAP earnings per share guidance to reflect the stronger-than-expected results over the first nine months of 2026 and remain confident in our team’s ability to execute, with attractive constant currency growth, improving profitability, and solid cash flow generation this year. Our team remains focused on delivering our Continued Growth Initiative financial targets for the three-year period ending December 31, 2026, and, in parallel, we are finalizing our longer-term strategic plan focused on identifying opportunities to better position the company for sustainable growth, enhanced profitability and value creation for our shareholders.”

Merit’s revenue by product category for the three and nine-month periods ended September 30, 2026 and 2025 was as follows (unaudited; in thousands, except for percentages):


		Three Months Ended
		Reported									Constant Currency*
		September 30,							Impact of foreign		September 30,
		2026			2025		% Change		exchange		2026		% Change
Foundational
Access		$	157,922		$	151,508	4	%	$	(1,018)	$	156,904	4	%
OEM			46,278			41,499	12	%		47		46,325	12	%
Procedural Solutions			27,162			32,287	(16)	%		184		27,346	(15)	%
Vascular Intervention			42,367			35,391	20	%		(166)		42,201	19	%
Other			2,006			221	808	%		547		2,553	1,055	%
Total Foundational			275,735			260,906	6	%		(406)		275,329	6	%

Therapeutic
Cardiac Therapies			27,547			25,530	8	%		(53)		27,494	8	%
Endoscopy			23,428			17,631	33	%		36		23,464	33	%
OEM			13,089			9,953	32	%		(16)		13,073	31	%
Oncology			27,085			23,263	16	%		(24)		27,061	16	%
Renal Therapies			13,550			13,808	(2)	%		(123)		13,427	(3)	%
Vascular Intervention			35,810			33,066	8	%		(496)		35,314	7	%
Total Therapeutic			140,509			123,251	14	%		(676)		139,833	13	%

Total		$	416,244		$	384,157	8	%	$	(1,082)	$	415,162	8	%


		Nine Months Ended
		Reported									Constant Currency *
		September 30,							Impact of foreign		September 30,
		2026			2025		% Change		exchange		2026		% Change
Foundational
Access		$	470,832		$	438,028	7	%	$	(8,538)	$	462,294	6	%
OEM			134,156			128,140	5	%		(217)		133,939	5	%
Procedural Solutions			81,599			92,597	(12)	%		166		81,765	(12)	%
Vascular Intervention			123,057			103,195	19	%		(1,638)		121,419	18	%
Other			2,531			1,710	48	%		3,296		5,827	241	%
Total Foundational			812,175			763,670	6	%		(6,931)		805,244	5	%

Therapeutic
Cardiac Therapies			83,461			69,019	21	%		(1,747)		81,714	18	%
Endoscopy			68,767			52,582	31	%		56		68,823	31	%
OEM			33,365			30,830	8	%		(66)		33,299	8	%
Oncology			76,367			69,257	10	%		(550)		75,817	9	%
Renal Therapies			37,775			40,014	(6)	%		(515)		37,260	(7)	%
Vascular Intervention			105,054			96,598	9	%		(2,252)		102,802	6	%
Total Therapeutic			404,789			358,300	13	%		(5,074)		399,715	12	%

Total		$	1,216,964		$	1,121,970	8	%	$	(12,005)	$	1,204,959	7	%

Financial Summary:

GAAP gross margin was 48.2%, compared to 48.5% for the third quarter of 2025. Non-GAAP gross margin* was 52.8%, compared to 53.6% for the third quarter of 2025.

GAAP operating margin was 14.1%, compared to 11.1% for the third quarter of 2025. Non-GAAP operating margin* was 21.3%, compared to 19.7% for the third quarter of 2025.

GAAP net income was $42.3 million, or $0.70 per share, compared to $27.8 million, or $0.46 per share, for the third quarter of 2025. Non-GAAP net income* was $67.4 million, or $1.12 per share, compared to $54.9 million, or $0.92 per share, for the third quarter of 2025.

As of September 30, 2026, Merit had cash and cash equivalents of $503.6 million and total debt obligations of $747.5 million, compared to cash and cash equivalents of $446.4 million and total debt obligations of $747.5 million as of December 31, 2025. Merit had available borrowing capacity of approximately $697 million as of September 30, 2026.

Fiscal Year 2026 Financial Guidance

Based upon the information currently available to Merit’s management, for the twelve-month period ending December 31, 2026, absent the potential impact of trade policies and related actions implemented by the U.S. and other countries subsequent to today’s date, material acquisitions, non-recurring transactions or other factors beyond Merit’s current expectations, Merit anticipates the following financial results:

Revenue and Earnings Guidance*


		Updated Guidance		Prior Guidance⁽²⁾
		Year Ending	% Change	Year Ending	% Change
Financial Measure		December 31, 2026	Y/Y	December 31, 2026	Y/Y
Total Revenue		$1.635 - $1.642 billion	8% - 8%	$1.631 - $1.643 billion	8% - 8%

Non-GAAP Earnings Per Share⁽¹⁾		$4.33 - $4.37	13% - 14%	$4.25 - $4.35	11% - 14%

*Percentage figures approximated; dollar figures may not foot due to rounding.

(1) Merit’s non-GAAP earnings per share reflect the dilutive impact of its 3.00% Convertible Senior Notes due 2029 (the “Convertible Notes”) calculated using the if-converted method of approximately $0.01 per share for the year ending December 31, 2026. Any offsetting impacts of the capped call associated with the Convertible Notes are not considered.

(2) “Prior Guidance” reflects Merit’s full-year 2026 financial guidance, previously introduced on July 30, 2026.

Merit does not provide guidance for GAAP reported financial measures (other than revenue) or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures (other than revenue) because Merit is unable to predict with reasonable certainty the financial impact of various items which could impact Merit’s future financial results, such as expenses attributable to acquisitions or other extraordinary transactions, non-cash expenses related to amortization or write-off of previously acquired tangible and intangible assets, certain employee termination benefits, performance-based stock compensation expenses, expenses resulting from non-ordinary course litigation or administrative proceedings and resulting settlements, governmental proceedings, and changes in governmental or industry regulations. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For the same reasons, Merit is unable to address the significance of the unavailable information, which could be material to future results. Specifically, Merit is not, without unreasonable effort, able to reasonably predict the amount and impact of these items and Merit believes inclusion of the most comparable GAAP financial measure, and a reconciliation of these forward-looking non-GAAP measures to their GAAP counterparts could be confusing to investors or cause undue reliance.

Merit’s financial guidance for the year ending December 31, 2026 is subject to risks and uncertainties identified in this release and Merit’s filings with the SEC. This guidance is based on information and estimates available to Merit as of October 29, 2026. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results will likely vary, and could vary materially, from past results and those anticipated, estimated or projected.

CONFERENCE CALL

As previously announced, Merit will hold its investor conference call today, Thursday, October 29, 2026, at 4:30 p.m., Eastern Time, to discuss its results for the third quarter and provide an operational update. To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details. A live webcast and slide deck will also be available at merit.com.

CONSOLIDATED BALANCE SHEETS

(in thousands)

fp
	September 30,		December 31,
	2026		2025
ASSETS	(Unaudited)
Current Assets
Cash and cash equivalents	$	503,551	$	446,404
Trade receivables, net		221,866		203,710
Other receivables		37,875		17,773
Inventories		391,022		333,705
Prepaid expenses and other current assets		35,188		31,493
Prepaid income taxes		5,030		4,941
Income tax refund receivables		4,283		2,128
Total current assets		1,198,815		1,040,154

Property and equipment, net		437,347		428,401
Intangible assets, net		591,204		537,654
Goodwill		537,135		506,837
Deferred income tax assets		7,273		7,049
Right-of-use operating lease assets		84,379		87,600
Other assets		68,753		78,227
Total Assets	$	2,924,906	$	2,685,922

LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities
Trade payables	$	66,286	$	60,551
Accrued expenses		174,024		159,486
Short-term operating lease liabilities		10,382		10,876
Income taxes payable		14,391		8,851
Total current liabilities		265,083		239,764

Long-term debt		737,404		734,038
Deferred income tax liabilities		37,216		19,665
Liabilities related to unrecognized tax benefits		2,248		2,248
Deferred compensation payable		19,373		17,542
Deferred credits		1,321		1,398
Long-term operating lease liabilities		74,273		76,658
Other long-term obligations		43,437		10,306
Total liabilities		1,180,355		1,101,619

Stockholders' Equity
Common stock		808,930		763,909
Retained earnings		946,139		824,030
Accumulated other comprehensive loss		(10,518)		(3,636)
Total stockholders' equity		1,744,551		1,584,303
Total Liabilities and Stockholders' Equity	$	2,924,906	$	2,685,922

CONSOLIDATED STATEMENTS OF INCOME

(Unaudited, in thousands except per share amounts)


		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2026			2025			2026			2025
Net sales		$	416,244		$	384,157		$	1,216,964		$	1,121,970
Cost of sales			215,613			197,746			616,370			579,052
Gross profit			200,631			186,411			600,594			542,918

Operating expenses:
Selling, general and administrative			119,511			119,801			366,950			340,384
Research and development			22,393			23,966			70,391			70,811
Contingent consideration (benefit) expense			(36)			32			(70)			1,198
Total operating expenses			141,868			143,799			437,271			412,393

Income from operations			58,763			42,612			163,323			130,525

Other income (expense):
Interest income			4,128			3,615			11,780			11,166
Interest expense			(7,333)			(6,754)			(25,977)			(20,097)
Other income (expense) — net			227			(933)			11,519			(1,717)
Total other expense — net			(2,978)			(4,072)			(2,678)			(10,648)

Income before income taxes			55,785			38,540			160,645			119,877

Income tax expense			13,474			10,785			38,536			29,394

Net income		$	42,311		$	27,755		$	122,109		$	90,483

Earnings per common share
Basic		$	0.71		$	0.47		$	2.05		$	1.53
Diluted		$	0.70		$	0.46		$	2.03		$	1.49

Weighted average shares outstanding
Basic			59,806			59,245			59,666			59,095
Diluted			60,379			59,919			60,134			60,604

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited, in thousands)


		Nine Months Ended
		September 30,
		2026			2025
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income		$	122,109		$	90,483
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization			93,383			91,629
Gain on disposition of a business			(12,557)			(249)
Amortization of right-of-use operating lease assets			8,771			8,693
Fair value adjustments related to contingent consideration liabilities			(70)			1,198
Stock-based compensation expense			35,497			33,563
Other adjustments			6,950			5,123
Changes in operating assets and liabilities, net of acquisitions and divestitures			(78,853)			(31,579)
Total adjustments			53,121			108,378
Net cash, cash equivalents, and restricted cash provided by operating activities			175,230			198,861

CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures for property and equipment			(45,686)			(57,252)
Proceeds from asset and business dispositions			25,555			298
Cash paid for notes receivable and other investments			(9,242)			(14,936)
Cash paid in acquisitions, net of cash acquired			(93,049)			(122,834)
Other investing, net			(2,293)			(2,327)
Net cash, cash equivalents, and restricted cash used in investing activities			(124,715)			(197,051)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock			16,272			22,179
Contingent payments related to acquisitions			(3,030)			(2,645)
Payment of taxes related to an exchange of common stock			(6,973)			(8,597)
Net cash, cash equivalents, and restricted cash provided by financing activities			6,269			10,937
Effect of exchange rates on cash			454			3,047
Net increase in cash, cash equivalents and restricted cash			57,238			15,794

CASH, CASH EQUIVALENTS AND RESTRICTED CASH:
Beginning of period			448,549			378,767
End of period		$	505,787		$	394,561

RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH TO THE CONSOLIDATED BALANCE SHEETS:
Cash and cash equivalents			503,551			392,457
Restricted cash reported in prepaid expenses and other current assets			2,236			2,104
Total cash, cash equivalents and restricted cash		$	505,787		$	394,561

Non-GAAP Financial Measures

Although Merit’s financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”), Merit’s management believes that the non-GAAP financial measures referenced in this release may provide investors with useful information regarding the underlying business trends and performance of Merit’s ongoing operations and can be useful for period-over-period comparisons of such operations. Non-GAAP financial measures used in this release include:

●

constant currency revenue;

●

constant currency revenue, organic;

●

non-GAAP gross profit and margin;

●

non-GAAP operating income and margin;

●

non-GAAP net income;

●

non-GAAP earnings per share; and

●

free cash flow.

Merit’s management team uses these non-GAAP financial measures to evaluate Merit’s profitability and efficiency, to compare operating and financial results to prior periods, to evaluate changes in the results of its operating segment, and to measure and allocate financial resources internally. However, Merit’s management does not consider such non-GAAP measures in isolation or as an alternative to measures determined in accordance with GAAP.

Readers should consider non-GAAP measures used in this release in addition to, not as a substitute for, financial reporting measures prepared in accordance with GAAP. These non-GAAP financial measures generally exclude some, but not all, items that may affect Merit’s net income. In addition, they are subject to inherent limitations as they reflect the exercise of judgment by management about which items are excluded. Merit believes it is useful to exclude such items in the calculation of non-GAAP gross profit and margin, non-GAAP operating income and margin, non-GAAP net income, and non-GAAP earnings per share (in each case, as further illustrated in the reconciliation tables below) because such amounts in any specific period may not directly correlate to the underlying performance of Merit’s business operations and can vary significantly between periods as a result of factors such as acquisition or other extraordinary transactions, non-cash expenses related to amortization or write-off of previously acquired tangible and intangible assets, certain employee termination benefits, expenses resulting from non-ordinary course litigation or administrative proceedings and resulting settlements, governmental proceedings or changes in tax or industry regulations, gains or losses on disposal of certain assets, equity method investment loss (income) from equity investees, and debt issuance costs. Merit may incur similar types of expenses in the future, and the non-GAAP financial information included in this release should not be viewed as a statement or indication that these types of expenses will not recur. Additionally, the non-GAAP financial measures used in this release may not be comparable with similarly titled measures of other companies. Merit urges readers to review the reconciliations of its non-GAAP financial measures to their most directly comparable GAAP financial measures included herein, and not to rely on any single financial measure to evaluate Merit’s business or results of operations.

Constant Currency Revenue

Merit’s constant currency revenue is prepared by converting the current-period reported revenue of subsidiaries whose functional currency is a currency other than the U.S. dollar at the applicable foreign exchange rates in effect during the comparable prior-year period and adjusting for the effects of hedging transactions on reported revenue, which are recorded in the U.S. dollar. The constant currency revenue adjustment of $(1.1) million and $(12.0) million to reported revenue for the three and nine-month periods ended September 30, 2026 was calculated using the applicable average foreign exchange rates for the three and nine-month periods ended September 30, 2025.

Constant Currency Revenue, Organic

Merit’s constant currency revenue, organic, is defined, with respect to prior fiscal year periods, as GAAP revenue less revenue from certain divestitures. For the three and nine-month periods ended September 30, 2025, Merit’s constant currency revenue, organic, excludes revenues attributable to the DualCap® product line which Merit sold to Health Line International Corporation (“Health Line”) on February 17, 2026 (the “DualCap Divestiture”).

With respect to current fiscal year periods, constant currency revenue, organic, is defined as constant currency revenue (as defined above), less revenue from certain acquisitions and divestitures. For the three-month period ended September 30, 2026, Merit’s constant currency revenue, organic, excludes revenues attributable to products acquired in connection with (i) Merit’s acquisition of View Point Medical, Inc. (“View Point”) in April 2026 (the “View Point Merger”) and (ii) the assets acquired from Pentax of America, Inc. related to the C2 CryoBalloon™ device in November 2025 (the “C2 Acquisition”). For the nine-month period ended September 30, 2026, Merit’s constant currency revenue, organic, excludes revenues attributable to products acquired in connection with (i) the View Point Merger, (ii) the C2 Acquisition and (iii) Merit’s acquisition of Biolife Delaware, L.L.C. (“Biolife”) in May 2025 (the “Biolife Merger”) and excludes revenues attributable to the DualCap Divestiture.

Non-GAAP Gross Profit and Margin

Non-GAAP gross profit is calculated by reducing GAAP cost of sales by amounts recorded for amortization of intangible assets and inventory mark-up related to acquisitions. Non-GAAP gross margin is calculated by dividing non-GAAP gross profit by reported net sales.

Non-GAAP Operating Income and Margin

Non-GAAP operating income is calculated by adjusting GAAP operating income for certain items which are deemed by Merit’s management to be outside of core operations and vary in amount and frequency among periods, such as expenses related to acquisitions or other extraordinary transactions, non-cash expenses related to amortization or write-off of previously acquired tangible and intangible assets, certain employee termination benefits, performance-based stock compensation expenses, expenses resulting from non-ordinary course litigation or administrative proceedings and resulting settlements, governmental proceedings, and changes in governmental or industry regulations, as well as other items referenced in the tables below. Non-GAAP operating margin is calculated by dividing non-GAAP operating income by reported net sales.

Non-GAAP Net Income

Non-GAAP net income is calculated by adjusting GAAP net income for the items set forth in the definition of non-GAAP operating income above, as well as for expenses related to Merit’s long-term debt, gains or losses on disposal of certain assets, equity method investment loss (income) from equity investees, and other items set forth in the tables below.

Non-GAAP EPS

Non-GAAP EPS is defined as non-GAAP net income divided by the diluted shares outstanding for the corresponding period.

Free Cash Flow

Free cash flow is defined as cash flow from operations calculated in accordance with GAAP, less capital expenditures for property and equipment calculated in accordance with GAAP, as set forth in the consolidated statement of cash flows.

Other Non-GAAP Financial Measure Reconciliations

The following tables set forth supplemental financial data and corresponding reconciliations of non-GAAP financial measures to Merit’s corresponding financial measures prepared in accordance with GAAP, in each case, for the three and nine-month periods ended September 30, 2026 and 2025. The non-GAAP income adjustments referenced in the following tables do not reflect non-performance-based stock compensation expense of $6.4 million and $4.6 million for the three-month periods ended September 30, 2026 and 2025, respectively, and $15.9 million and $13.9 million for the nine-month periods ended September 30, 2026 and 2025, respectively.

Reconciliation of GAAP Net Income to Non-GAAP Net Income

(Unaudited, in thousands except per share amounts)


	Three Months Ended
	September 30, 2026
	Pre-Tax		Tax Impact		After-Tax		Per Share Impact
GAAP net income	$	55,785	$	(13,474)	$	42,311	$	0.70

Non-GAAP adjustments:
Cost of Sales
Amortization of intangibles		18,996		(4,484)		14,512		0.24
Operating Expenses
Contingent consideration benefit		(36)		(14)		(50)		(0.00)
Amortization of intangibles		2,540		(600)		1,940		0.03
Performance-based share-based compensation (a)		7,173		(665)		6,508		0.11
Corporate restructuring (b)		301		(71)		230		0.00
Acquisition-related		280		(11)		269		0.00
Medical Device Regulation expenses (c)		519		(123)		396		0.01
Other (Income) Expense
Long-term debt costs (e)		1,414		(334)		1,080		0.02
Other non-operating loss (f)		254		(60)		194		0.00

Non-GAAP net income	$	87,226	$	(19,836)	$	67,390	$	1.12

Diluted shares								60,379


	Three Months Ended
	September 30, 2025
	Pre-Tax		Tax Impact		After-Tax		Per Share Impact
GAAP net income	$	38,540	$	(10,785)	$	27,755	$	0.46

Non-GAAP adjustments:
Cost of Sales
Amortization of intangibles		19,212		(4,539)		14,673		0.24
Inventory mark-up related to acquisitions		183		(43)		140		0.00
Operating Expenses
Contingent consideration expense		32		(5)		27		0.00
Amortization of intangibles		2,560		(604)		1,956		0.03
Performance-based share-based compensation (a)		9,028		(1,413)		7,615		0.13
Corporate restructuring (b)		286		(67)		219		0.00
Acquisition-related		(68)		16		(52)		(0.00)
Medical Device Regulation expenses (c)		1,655		(391)		1,264		0.02
Other (d)		74		(17)		57		0.00
Other (Income) Expense
Long-term debt costs (e)		1,414		(334)		1,080		0.02
Other non-operating loss (f)		260		(61)		199		0.00

Non-GAAP net income	$	73,176	$	(18,243)	$	54,933	$	0.92

Diluted shares								59,919

Note: Certain per-share impacts may not sum to totals due to rounding.

Reconciliation of GAAP Net Income to Non-GAAP Net Income

(Unaudited, in thousands except per share amounts)


	Nine Months Ended
	September 30, 2026
	Pre-Tax		Tax Impact		After-Tax		Per Share Impact
GAAP net income	$	160,645	$	(38,536)	$	122,109	$	2.03

Non-GAAP adjustments:
Cost of Sales
Amortization of intangibles		55,941		(13,206)		42,735		0.71
Operating Expenses
Contingent consideration benefit		(70)		(9)		(79)		(0.00)
Amortization of intangibles		7,490		(1,768)		5,722		0.10
Performance-based share-based compensation (a)		19,602		(1,727)		17,875		0.30
Corporate restructuring (b)		2,460		(581)		1,879		0.03
Acquisition-related		7,091		(916)		6,175		0.10
Medical Device Regulation expenses (c)		2,589		(611)		1,978		0.03
Other (Income) Expense
Long-term debt costs (e)		9,305		(2,197)		7,108		0.12
Gain on disposal of business unit		(12,502)		1,520		(10,982)		(0.18)
Other non-operating loss (f)		1,079		(267)		812		0.01

Non-GAAP net income	$	253,630	$	(58,298)	$	195,332	$	3.25

Diluted shares								60,134


	Nine Months Ended
	September 30, 2025
	Pre-Tax		Tax Impact		After-Tax		Per Share Impact
GAAP net income	$	119,877	$	(29,394)	$	90,483	$	1.49

Non-GAAP adjustments:
Cost of Sales
Amortization of intangibles		55,798		(13,184)		42,614		0.70
Inventory mark-up related to acquisitions		250		(59)		191		0.00
Operating Expenses
Contingent consideration expense		1,198		29		1,227		0.02
Amortization of intangibles		7,497		(1,771)		5,726		0.09
Performance-based share-based compensation (a)		19,681		(2,344)		17,337		0.29
Corporate restructuring (b)		2,873		(678)		2,195		0.04
Acquisition-related		2,088		(2)		2,086		0.03
Medical Device Regulation expenses (c)		4,883		(1,153)		3,730		0.06
Other (d)		103		(24)		79		0.00
Other (Income) Expense
Long-term debt costs (e)		4,242		(1,002)		3,240		0.05
Other non-operating loss (f)		11		(61)		(50)		(0.00)

Non-GAAP net income	$	218,501	$	(49,643)	$	168,858	$	2.79

Diluted shares								60,604

Note: Certain per-share impacts may not sum to totals due to rounding.

Reconciliation of Reported Operating Income to Non-GAAP Operating Income

(Unaudited, in thousands except percentages)


	Three Months Ended				Three Months Ended				Nine Months Ended				Nine Months Ended
	September 30, 2026				September 30, 2025				September 30, 2026				September 30, 2025
	Amounts		% Sales		Amounts		% Sales		Amounts		% Sales		Amounts		% Sales
Net Sales as Reported	$	416,244			$	384,157			$	1,216,964			$	1,121,970

GAAP Operating Income		58,763	14.1	%		42,612	11.1	%		163,323	13.4	%		130,525	11.6	%
Cost of Sales
Amortization of intangibles		18,996	4.6	%		19,212	5.0	%		55,941	4.6	%		55,798	5.0	%
Inventory mark-up related to acquisitions		—	—			183	0.0	%		—	—			250	0.0	%
Operating Expenses
Contingent consideration (benefit) expense		(36)	(0.0)	%		32	0.0	%		(70)	(0.0)	%		1,198	0.1	%
Amortization of intangibles		2,540	0.6	%		2,560	0.7	%		7,490	0.6	%		7,497	0.7	%
Performance-based share-based compensation (a)		7,173	1.7	%		9,028	2.4	%		19,602	1.6	%		19,681	1.8	%
Corporate restructuring (b)		301	0.1	%		286	0.1	%		2,460	0.2	%		2,873	0.3	%
Acquisition-related		280	0.1	%		(68)	(0.0)	%		7,091	0.6	%		2,088	0.2	%
Medical Device Regulation expenses (c)		519	0.1	%		1,655	0.4	%		2,589	0.2	%		4,883	0.4	%
Other (d)		—	—			74	0.0	%		—	—			103	0.0	%

Non-GAAP Operating Income	$	88,536	21.3	%	$	75,574	19.7	%	$	258,426	21.2	%	$	224,896	20.0	%

Note: Certain percentages may not sum to totals due to rounding.

(a)	Represents performance-based share-based compensation expense, including stock-settled and cash-settled awards.

(b)	Includes employee termination benefits associated with activities related to corporate restructuring initiatives and costs to terminate certain distribution contracts from the Biolife Merger.

(c)	Represents incremental expenses incurred to comply with the E.U. Medical Device Regulation.

(d)	Represents costs to comply with Merit’s corporate integrity agreement with the U.S. Department of Justice.

(e)	Represents costs associated with the Convertible Notes including the amortization of debt issuance costs and, for the nine-months ended September 30, 2026, a one-time charge for additional interest incurred pursuant to Merit's obligation to remove restrictive legends.

(f)	Includes equity method investment loss from equity investees.

Reconciliation of Reported Revenue to Constant Currency Revenue (Non-GAAP), and Constant Currency Revenue, Organic (Non-GAAP)

(Unaudited, in thousands except percentages)


			Three Months Ended						Nine Months Ended
			September 30,						September 30,
	% Change		2026		2025		% Change		2026		2025
Reported Revenue	8.4	%	$	416,244	$	384,157	8.5	%	$	1,216,964	$	1,121,970

Add: Impact of foreign exchange				(1,082)		—				(12,005)		—

Constant Currency Revenue (a)	8.1	%	$	415,162	$	384,157	7.4	%	$	1,204,959	$	1,121,970

Less: Revenue from certain acquisitions				(2,634)		—				(16,338)		—
Less: Revenue from divestitures (b)				—		(5,228)				(1,644)		(15,440)

Constant Currency Revenue, Organic (a)	8.9	%	$	412,528	$	378,929	7.3	%	$	1,186,977	$	1,106,530

(a)	A non-GAAP financial measure. For a definition of this and other non-GAAP financial measures, see the section of this release entitled “Non-GAAP Financial Measures.”

(b)	On February 17, 2026, Merit consummated the DualCap Divestiture for consideration of $28 million, of which $25.5 million was paid to Merit at closing.

Reconciliation of Reported Gross Margin to Non-GAAP Gross Margin (Non-GAAP)

(Unaudited, as a percentage of reported revenue)


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2026		2025		2026		2025
Reported Gross Margin	48.2	%	48.5	%	49.4	%	48.4	%

Add back impact of:
Amortization of intangibles	4.6	%	5.0	%	4.6	%	5.0	%
Inventory mark-up related to acquisitions	—	%	0.0	%	—	%	0.0	%

Non-GAAP Gross Margin	52.8	%	53.6	%	53.9	%	53.4	%

Note: Certain percentages may not sum to totals due to rounding.

Reconciliation of Reported Cash Flow from Operations to Free Cash Flow (Non-GAAP)

(Unaudited, in thousands)


	Nine Months Ended
	September 30,
	2026		2025
Reported Cash Flow from Operations	$	175,230	$	198,861

Less: Capital Expenditures		(45,686)		(57,252)

Free Cash Flow	$	129,544	$	141,609

Reconciliation of 2026 Net Sales Guidance - % Change from Prior Year (Constant Currency)


	Updated Guidance		Prior Guidance⁽¹⁾
	Low	High	Low	High
2026 Net Sales Guidance - % Change from Prior Year (GAAP)	7.9%	8.4%	7.6%	8.4%
Estimated impact of foreign currency exchange rate fluctuations	(0.8%)	(0.8%)	(0.8%)	(0.8%)
2026 Net Sales Guidance - % Change from Prior Year (Constant Currency)	7.0%	7.5%	6.8%	7.6%

Note: Certain percentages may not sum to totals due to rounding.

(1) “Prior Guidance” reflects Merit’s full-year 2026 financial guidance, previously introduced on July 30, 2026.

ABOUT MERIT

Founded in 1987, Merit is engaged in the development, manufacture, and distribution of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves customers worldwide with a domestic and international sales force and clinical support team totaling approximately 900 individuals. Merit employs approximately 7,500 people worldwide.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among others:

●

statements preceded or followed by, or that include the words, “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “intends,” “seeks,” “believes,” “estimates,” “projects,” “forecasts,” “potential,” “target,” “continue,” “upcoming,” “optimistic” or other forms of these words or similar words or expressions, or the negative thereof or other comparable terminology;

●

statements that address Merit’s future operating performance or events or developments that Merit’s management expects or anticipates will occur, including, without limitation, any statements regarding Merit’s projected revenues, earnings or other future financial measures, Merit’s plans and objectives for future operations, Merit’s proposed new products or services, the integration, development or commercialization of the business or any assets acquired from other parties, future economic conditions or performance, the implementation of, and results which may be achieved through, Merit’s Continued Growth Initiatives Program or other business optimization initiatives, and any statements of assumptions underlying any of the foregoing; and

●

statements regarding Merit’s past performance, efforts, or results about which inferences or assumptions may be made, including statements preceded or followed by the words "preliminary," "initial," "potential," "possible," "diligence," "industry-leading," "compliant," "indications" or "early feedback" or other forms of these words or similar words or expressions, or the negative thereof or other comparable terminology.

The forward-looking statements contained in this release are based on Merit management’s current expectations and assumptions regarding future events or outcomes. If underlying expectations or assumptions prove inaccurate, or risks or uncertainties materialize, actual results will likely differ, and may differ materially, from Merit’s expectations reflected in any forward-looking statements. Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results. Investors are cautioned not to unduly rely on any such forward-looking statements.

The following are some of the important risks and uncertainties that could cause Merit’s actual results to differ from management’s expectations in any forward-looking statements: risks and uncertainties arising from the conflict among the United States, Israel and Iran and related geopolitical instability; risks and uncertainties associated with Merit’s acquisition of Solo Pace, Inc. (“Solo Pace”) and SOLO PACE CONTROL and FUSION systems and related technology in October 2026; risks and uncertainties associated with Merit’s integration of the Solo Pace business, assets and operations into its operations and its ability to achieve anticipated financial results, product development and other anticipated benefits of the acquisition; uncertainties as to whether Merit will achieve revenue or other financial performance consistent with its forecasts projected for the Solo Pace acquisition; risks and uncertainties regarding trade policies or related actions implemented by the United States or other countries, including existing, proposed, prospective or invalidated tariffs, duties or other measures; risks and uncertainties associated with Merit’s integration of businesses or assets acquired from third parties, including the View Point Merger in April 2026, the C2 Acquisition in November 2025 and the Biolife Merger in May 2025, and Merit’s ability to achieve the anticipated operating and financial results, product development and other anticipated benefits of such acquisitions; effects of Merit’s 3.00% Convertible Senior Notes due 2029 on Merit’s net income and earnings per share performance; disruptions in Merit’s supply chain, manufacturing or sterilization processes; U.S. and global political, economic, competitive, reimbursement and regulatory conditions; risks and uncertainties associated with Merit’s executive succession and leadership transition; modification or limitation of, or policies and procedures associated with, governmental or private insurance reimbursement policies; reduced availability of, and price increases associated with, components and other raw materials; increases in transportation expenses; risks relating to Merit’s potential inability to successfully manage growth through acquisitions generally, including the inability to effectively integrate acquired operations or products or commercialize technology developed internally or acquired through completed, proposed or future transactions; prospective financial obligations or other uncertainties associated with Merit’s divestiture of its DualCap® anti-microbial cap product line in February 2026; fluctuations in interest or foreign currency exchange rates and inflation; cybersecurity events; government

scrutiny and regulation of the medical device industry; difficulties relating to development, testing and regulatory approval, clearance and maintenance of Merit’s products; the safety, efficacy and patient and physician adoption of Merit’s products; the ability to fully enroll and the outcomes of ongoing and future clinical trials and market studies relating to Merit’s products; litigation and other legal proceedings affecting Merit; risks and possible effects of any failure to comply with U.S. and foreign laws and regulations; restrictions on Merit’s liquidity or business operations resulting from its debt agreements; infringement of Merit’s technology or the assertion that Merit’s technology infringes the rights of other parties; product recalls and product liability claims; potential for significant adverse changes in governing regulations;, changes in tax laws and regulations in the United States or other jurisdictions or exposure to additional tax liabilities which may adversely affect Merit’s effective tax rate; termination of relationships with Merit’s suppliers, or failure of such suppliers to perform; development of new products and technology that could render Merit’s existing or future products obsolete; market acceptance of new products; failure to comply with applicable environmental laws; changes in key personnel; labor shortages and increases in labor costs; price and product competition; extreme weather events; and geopolitical events. For a further discussion of the risks and uncertainties and other factors that may affect Merit’s business, operations and financial condition, see Part I, Item 1A. “Risk Factors” in Merit’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC, which Merit updated in Part II, Item 1A. “Risk Factors” in Merit’s Quarterly Reports on Form 10-Q for each of the quarters ended March 31, 2026, June 30, 2026 and September 30, 2026.

All subsequent forward-looking statements attributable to Merit or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Actual results will likely differ, and may differ materially, from anticipated results. Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results. Those estimates and all other forward-looking statements included in this release are made only as of the date of this release, and except as otherwise required by applicable law, Merit assumes no obligation to update or disclose revisions to estimates and all other forward-looking statements.

TRADEMARKS

Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc., its subsidiaries, or its licensors.

# # #

Exhibit 99.2

1 Merit Medical Investor Call October 29, 2026 Third Quarter 2026 Results Martha Aronson President and CEO Raul Parra CFO

2 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among others:  statements preceded or followed by, or that include the words, “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “intends,” “seeks,” “believes,” “estimates,” “projects,” “forecasts,” “potential,” “target,” “continue,” “upcoming,” “optimistic” or other forms of these words or similar words or expressions, or the negative thereof or other comparable terminology;  statements that address Merit’s future operating performance or events or developments that Merit’s management expects or anticipates will occur, including, without limitation, any statements regarding Merit’s projected revenues, earnings or other future financial measures, Merit’s plans and objectives for future operations, Merit’s proposed new products or services, the integration, development or commercialization of the business or any assets acquired from other parties, future economic conditions or performance, the implementation of, and results which may be achieved through, Merit’s Continued Growth Initiatives Program or other business optimization initiatives, and any statements of assumptions underlying any of the foregoing; and  statements regarding Merit’s past performance, efforts, or results about which inferences or assumptions may be made, including statements preceded or followed by the words "preliminary," "initial," "potential," "possible," "diligence," "industry-leading," "compliant," "indications," or "early feedback" or other forms of these words or similar words or expressions, or the negative thereof or other comparable terminology. The forward-looking statements contained in this presentation are based on Merit management’s current expectations and assumptions regarding future events or outcomes. If underlying expectations or assumptions prove inaccurate, or risks or uncertainties materialize, actual results will likely differ, and may differ materially, from Merit’s expectations reflected in any forward-looking statements. Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results. Investors are cautioned not to unduly rely on any such forward-looking statements.

3 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS (CONTINUED) The following are some of the important risks and uncertainties that could cause Merit’s actual results to differ from management’s expectations in any forward-looking statements: risks and uncertainties arising from the conflict among the United States, Israel and Iran and related geopolitical instability; risks and uncertainties associated with Merit’s acquisition of Solo Pace, Inc. (“Solo Pace”) and SOLO PACE CONTROL and FUSION systems and related technology in October 2026; risks and uncertainties associated with Merit’s integration of the Solo Pace business, assets and operations into its operations and its ability to achieve anticipated financial results, product development and other anticipated benefits of the acquisition; uncertainties as to whether Merit will achieve revenue or other financial performance consistent with its forecasts projected for the Solo Pace acquisition; risks and uncertainties regarding trade policies or related actions implemented by the United States or other countries, including existing, proposed, prospective or invalidated tariffs, duties or other measures; risks and uncertainties associated with Merit’s integration of businesses or assets acquired from third parties, including View Point Medical, Inc. in April 2026 (the “View Point Merger”), the business and assets acquired from Pentax of America, Inc. related to the C2 CryoBalloon device in November 2025 (the “C2 Acquisition”) and Merit’s acquisition of Biolife Delaware, L.L.C. in May 2025 (the “Biolife Merger”), and Merit’s ability to achieve the anticipated operating and financial results, product development and other anticipated benefits of such acquisitions; effects of Merit’s 3.00% Convertible Senior Notes due 2029 on Merit’s net income and earnings per share performance; disruptions in Merit’s supply chain, manufacturing or sterilization processes; U.S. and global political, economic, competitive, reimbursement and regulatory conditions; risks and uncertainties associated with Merit’s executive succession and leadership transition; modification or limitation of, or policies and procedures associated with, governmental or private insurance reimbursement policies; reduced availability of, and price increases associated with, components and other raw materials; increases in transportation expenses; risks relating to Merit’s potential inability to successfully manage growth through acquisitions generally, including the inability to effectively integrate acquired operations or products or commercialize technology developed internally or acquired through completed, proposed or future transactions; prospective financial obligations or other uncertainties associated with Merit’s divestiture of its DualCap® anti-microbial product line which Merit sold to Health Line International Corporation (“Health Line”) on February 17, 2026 (the “DualCap Divestiture”); fluctuations in interest or foreign currency exchange rates and inflation; cybersecurity events; government scrutiny and regulation of the medical device industry; difficulties relating to development, testing and regulatory approval, clearance and maintenance of Merit’s products; the safety, efficacy and patient and physician adoption of Merit’s products; the ability to fully enroll and the outcomes of ongoing and future clinical trials and market studies relating to Merit’s products; litigation and other legal proceedings affecting Merit; risks and possible effects of any failure to comply with U.S. and foreign laws and regulations; restrictions on Merit’s liquidity or business operations resulting from its debt agreements; infringement of Merit’s technology or the assertion that Merit’s technology infringes the rights of other parties; product recalls and product liability claims; potential for significant adverse changes in governing regulations;, changes in tax laws and regulations in the United States or other jurisdictions or exposure to additional tax liabilities which may adversely affect Merit’s effective tax rate; termination of relationships with Merit’s suppliers, or failure of such suppliers to perform; development of new products and technology that could render Merit’s existing or future products obsolete; market acceptance of new products; failure to comply with applicable environmental laws; changes in key personnel; labor shortages and increases in labor costs; price and product competition; extreme weather events; and geopolitical events. For a further discussion of the risks and uncertainties and other factors that may affect Merit’s business, operations and financial condition, see Part I, Item 1A. “Risk Factors” in Merit’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC, which Merit updated in Part II, Item 1A. “Risk Factors” in Merit’s Quarterly Reports on Form 10-Q for each of the quarters ended March 31, 2026, June 30, 2026 and September 30, 2026. All subsequent forward-looking statements attributable to Merit or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Actual results will likely differ, and may differ materially, from anticipated results. Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results. Those estimates and all other forward-looking statements included in this presentation are made only as of the date of this presentation, and except as otherwise required by applicable law, Merit assumes no obligation to update or disclose revisions to estimates and all other forward-looking statements.

4 NON-GAAP FINANCIAL MEASURES Although Merit’s financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”), Merit’s management believes that certain non-GAAP financial measures provide investors with useful information regarding the underlying business trends and performance of Merit’s ongoing operations and can be useful for period-over-period comparisons of such operations. Certain financial measures included in this presentation, or which may be referenced in management’s discussion of Merit’s historical and future operations and financial results, have not been calculated in accordance with GAAP, and, therefore, are referenced as non-GAAP financial measures. Readers should consider non-GAAP measures used in this presentation in addition to, not as a substitute for, financial reporting measures prepared in accordance with GAAP. These non-GAAP financial measures generally exclude some, but not all, items that may affect Merit's net income. In addition, they are subject to inherent limitations as they reflect the exercise of judgment by management about which items are excluded. Additionally, non-GAAP financial measures used in this presentation may not be comparable with similarly titled measures of other companies. Merit urges readers to review the reconciliations of its non-GAAP financial measures to the comparable GAAP financial measures, and not to rely on any single financial measure to evaluate Merit’s business or results of operations. Please refer to “Notes to Non-GAAP Financial Measures” at the end of these materials for more information. TRADEMARKS Unless noted otherwise, trademarks and registered trademarks used in this presentation are the property of Merit Medical Systems, Inc., its subsidiaries, or its licensors.

5 Q3 2026 Q3 2025 % Change YTD 2026 YTD 2025 % Change Revenue $416.2M $384.2M 8.4% $1,217.0M $1,122.0M 8.5% Gross Margin 48.2% 48.5% (0.7)% 49.4% 48.4% 2.0% Operating Margin 14.1% 11.1% 27.3% 13.4% 11.6% 15.4% Net Income $42.3M $27.8M 52.4% $122.1M $90.5M 35.0% Earnings per Share $0.70 $0.46 51.3% $2.03 $1.49 36.0% Financial Summary: GAAP 5 Note: Amounts in this presentation are rounded while percentages are calculated from the underlying amounts. In millions, except per share amounts and percentages

6 Q3 2026 Q3 2025 % Change YTD 2026 YTD 2025 % Change $412.5M $378.9M 8.9% $1,187.0M $1,106.5M 7.3% Constant Currency Revenue, Organic* Non-GAAP Gross Margin* 52.8% 53.6% (1.5)% 53.9% 53.4% 1.1% Non-GAAP Operating Margin* 21.3% 19.7% 8.1% 21.2% 20.0% 5.9% Non-GAAP Net Income* $67.4M $54.9M 22.7% $195.3M $168.9M 15.7% Non-GAAP Earnings per Share* $1.12 $0.92 21.7% $3.25 $2.79 16.6% Financial Summary: Non-GAAP* 6 Note: Amounts in this presentation are rounded while percentages are calculated from the underlying amounts. * See "Notes to Non-GAAP Financial Measures" below for additional information regarding non-GAAP measures used in this presentation. In millions, except per share amounts and percentages

7 Revenue Breakdown – Q3 Region Q3 2026 Q3 2025 $ Change % Change CC % Change* Domestic $255,946 $230,597 $25,349 11.0% 11.2% International 160,298 153,560 6,738 4.4% 3.3% Total $416,244 $384,157 $32,087 8.4% 8.1% 7 Note: Amounts in this presentation are rounded while percentages are calculated from the underlying amounts. * A non-GAAP financial measure, representing revenue growth on a constant currency (“CC”) basis. See "Notes to Non-GAAP Financial Measures" below for additional information regarding non-GAAP measures used in this presentation. In thousands, except percentages

8 Revenue Breakdown – YTD Note: Amounts in this presentation are rounded while percentages are calculated from the underlying amounts. * A non-GAAP financial measure, representing revenue growth on a constant currency (“CC”) basis. See "Notes to Non-GAAP Financial Measures" below for additional information regarding non-GAAP measures used in this presentation. In thousands, except percentages Region YTD 2026 YTD 2025 $ Change % Change CC % Change* Domestic $734,513 $671,243 $63,270 9.4% 9.9% International 482,451 450,727 31,724 7.0% 3.7% Total $1,216,964 $1,121,970 $94,994 8.5% 7.4%

9 Financial Metrics Metric Q3 2026 Q3 2025 YTD 2026 YTD 2025 Depreciation & Amortization $31.9M $31.3M $93.4M $91.6M Stock Comp (performance-based) 7.2M 9.0M 19.6M 19.7M Stock Comp (not performance-based) 6.4M 4.6M 15.9M 13.9M Operating Cash Flow 65.3M 75.0M 175.2M 198.9M Capital Expenditures-Property and Equipment 12.3M 22.4M 45.7M 57.3M 9 In millions

10 Fiscal Year 2026 Financial Guidance Merit does not provide guidance for GAAP reported financial measures (other than revenue) or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures (other than revenue) because Merit is unable to predict with reasonable certainty the financial impact of various items which could impact Merit’s future financial results, such as expenses related to acquisitions or other extraordinary transactions, non-cash expenses related to amortization or write-off of previously acquired tangible and intangible assets, certain employee termination benefits, performance-based stock compensation expenses, expenses resulting from non-ordinary course litigation or administrative proceedings and resulting settlements, governmental proceedings, and changes in governmental or industry regulations. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For the same reasons, Merit is unable to address the significance of the unavailable information, which could be material to future results. Specifically, Merit is not, without unreasonable effort, able to reasonably predict the amount and impact of these items and Merit believes inclusion of the most comparable GAAP financial measure, and a reconciliation of these forward-looking non-GAAP measures to their GAAP counterparts could be confusing to investors or cause undue reliance. Merit’s financial guidance for the year ending December 31, 2026, is subject to risks and uncertainties identified in this presentation and Merit’s filings with the U.S. Securities and Exchange Commission (the “SEC”). This guidance is based on information and estimates available to Merit as of October 29, 2026. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results will likely vary, and could vary materially, from past results and those anticipated, estimated or projected. (1) “Prior Guidance” reflects Merit’s full-year 2026 financial guidance, previously introduced on July 30, 2026. * Percentage figures approximated; percentage and dollar figures may not foot due to rounding 2026 Net Sales Guidance - % Change from Prior Year (Constant Currency) Reconciliation* Revenue and Earnings Guidance* (1) Merit’s non-GAAP earnings per share reflect the dilutive impact of its 3.00% Convertible Senior Notes due 2029 calculated using the if-converted method of approximately $0.01 per share for the year ending December 31, 2026. Any offsetting impacts of the capped call associated with the Convertible Notes are not considered. (2) “Prior Guidance” reflects Merit’s full-year 2026 financial guidance, previously introduced on July 30, 2026. Year Ending % Change Year Ending % Change Financial Measure December 31, 2026 Y/Y December 31, 2026 Y/Y Total Revenue $1.635 - $1.642 billion 8% - 8% $1.631 - $1.643 billion 8% - 8% Non-GAAP Earnings Per Share(1) $4.33 - $4.37 13% - 14% $4.25 - $4.35 11% - 14% Updated Guidance Prior Guidance(2) Low High Low High 2026 Net Sales Guidance - % Change from Prior Year (GAAP) 7.9% 8.4% 7.6% 8.4% Estimated impact of foreign currency exchange rate fluctuations (0.8%) (0.8%) (0.8%) (0.8%) 2026 Net Sales Guidance - % Change from Prior Year (Constant Currency) 7.0% 7.5% 6.8% 7.6% Updated Guidance Prior Guidance(1)

11 Appendix

12 Notes to Non-GAAP Financial Measures For additional details, please see the accompanying press release and forward-looking statement disclosure. These presentation materials and associated commentary from Merit’s management, as well as the press release issued today, use non-GAAP financial measures, including: • constant currency revenue; • constant currency revenue, organic; • non-GAAP gross profit and margin; • non-GAAP operating income and margin; • non-GAAP net income; • non-GAAP earnings per share; and • free cash flow. Merit’s management team uses these non-GAAP financial measures to evaluate Merit’s profitability and efficiency, to compare operating and financial results to prior periods, to evaluate changes in the results of its operating segment, and to measure and allocate financial resources internally. However, Merit’s management does not consider such non-GAAP measures in isolation or as an alternative to measures determined in accordance with GAAP. Readers should consider non-GAAP measures used in this presentation in addition to, not as a substitute for, financial reporting measures prepared in accordance with GAAP. These non-GAAP financial measures generally exclude some, but not all, items that may affect Merit’s net income. In addition, they are subject to inherent limitations as they reflect the exercise of judgment by management about which items are excluded. Merit believes it is useful to exclude such items in the calculation of non-GAAP gross profit and margin, non-GAAP operating income and margin, non-GAAP net income, and non-GAAP earnings per share (in each case, as further illustrated in the reconciliation tables below) because such amounts in any specific period may not directly correlate to the underlying performance of Merit’s business operations and can vary significantly between periods as a result of factors such as acquisition or other extraordinary transactions, non-cash expenses related to amortization or write-off of previously acquired tangible and intangible assets, certain employee termination benefits, expenses resulting from non-ordinary course litigation or administrative proceedings and resulting settlements, governmental proceedings or changes in tax or industry regulations, gains or losses on disposal of certain assets, equity method investment loss (income) from equity investees, and debt issuance costs. Merit may incur similar types of expenses in the future, and the non-GAAP financial information included in this presentation should not be viewed as a statement or indication that these types of expenses will not recur. Additionally, the non-GAAP financial measures used in this presentation may not be comparable with similarly titled measures of other companies. Merit urges readers to review the reconciliations of its non-GAAP financial measures to their most directly comparable GAAP financial measures included herein, and not to rely on any single financial measure to evaluate Merit’s business or results of operations.

13 Notes to Non-GAAP Financial Measures (cont.) Constant Currency Revenue Merit’s constant currency revenue is prepared by converting the current-period reported revenue of subsidiaries whose functional currency is a currency other than the U.S. dollar at the applicable foreign exchange rates in effect during the comparable prior-year period and adjusting for the effects of hedging transactions on reported revenue, which are recorded in the U.S. dollar. The constant currency revenue adjustment of $(1.1) million and $(12.0) million to reported revenue for the three and nine-month periods ended September 30, 2026 was calculated using the applicable average foreign exchange rates for the three and nine-month periods ended September 30, 2025. Constant Currency Revenue, Organic Merit’s constant currency revenue, organic, is defined, with respect to prior fiscal year periods, as GAAP revenue less revenue from certain divestitures. For the three and nine-month periods ended September 30, 2025, Merit’s constant currency revenue, organic, excludes revenues attributable to the DualCap Divestiture. With respect to current fiscal year periods, constant currency revenue, organic, is defined as constant currency revenue (as defined above), less revenue from certain acquisitions and divestitures. For the three-month period ended September 30, 2026, Merit’s constant currency revenue, organic, excludes revenues attributable to products acquired in connection with (i) the View Point Merger and (ii) the C2 Acquisition. For the nine-month period ended September 30, 2026, Merit’s constant currency revenue, organic, excludes revenues attributable to products acquired in connection with (i) the View Point Merger, (ii) the C2 Acquisition and (iii) the Biolife Merger and excludes revenues attributable to the DualCap Divestiture. Non-GAAP Gross Profit and Margin Non-GAAP gross profit is calculated by reducing GAAP cost of sales by amounts recorded for amortization of intangible assets and inventory mark-up related to acquisitions. Non-GAAP gross margin is calculated by dividing non-GAAP gross profit by reported net sales.

14 Notes to Non-GAAP Financial Measures (cont.) Non-GAAP Operating Income and Margin Non-GAAP operating income is calculated by adjusting GAAP operating income for certain items which are deemed by Merit’s management to be outside of core operations and vary in amount and frequency among periods, such as expenses related to acquisitions or other extraordinary transactions, non-cash expenses related to amortization or write-off of previously acquired tangible and intangible assets, certain employee termination benefits, performance-based stock compensation expenses, expenses resulting from non-ordinary course litigation or administrative proceedings and resulting settlements, governmental proceedings, and changes in governmental or industry regulations, as well as other items referenced in the tables below. Non-GAAP operating margin is calculated by dividing non-GAAP operating income by reported net sales. Non-GAAP Net Income Non-GAAP net income is calculated by adjusting GAAP net income for the items set forth in the definition of non-GAAP operating income above, as well as for expenses related to our long-term debt, gains or losses on disposal of certain assets, equity method investment loss (income) from equity investees, and other items set forth in the tables below. Non-GAAP EPS Non-GAAP EPS is defined as non-GAAP net income divided by the diluted shares outstanding for the corresponding period. Free Cash Flow Free cash flow is defined as cash flow from operations calculated in accordance with GAAP, less capital expenditures for property and equipment calculated in accordance with GAAP, as set forth in the consolidated statement of cash flows. Other Non-GAAP Financial Measure Reconciliations The following tables set forth supplemental financial data and corresponding reconciliations of non-GAAP financial measures to Merit’s corresponding financial measures prepared in accordance with GAAP, in each case, for the three and nine-month periods ended September 30, 2026 and 2025. The non-GAAP income adjustments referenced in the following tables do not reflect non-performance-based stock compensation expense of $6.4 million and $4.6 million for the three-month periods ended September 30, 2026 and 2025, respectively, and $15.9 million and $13.9 million for the nine-month periods ended September 30, 2026 and 2025, respectively.

15 Reconciliation of GAAP Net Income to Non-GAAP Net Income (Unaudited; in thousands except per share amounts) Note: Certain per-share impacts may not sum to totals due to rounding. GAAP net income $ 55,785 $ (13,474) $ 42,311 $ 0.70 $ 38,540 $ (10,785) $ 27,755 $ 0.46 Non-GAAP adjustments: Cost of Sales Amortization of intangibles 18,996 (4,484) 14,512 0.24 19,212 (4,539) 14,673 0.24 Inventory mark-up related to acquisitions — — — — 183 (43) 140 0.00 Operating Expenses Contingent consideration (benefit) expense (36) (14) (50) (0.00) 32 (5) 27 0.00 Amortization of intangibles 2,540 (600) 1,940 0.03 2,560 (604) 1,956 0.03 Performance-based share-based compensation (a) 7,173 (665) 6,508 0.11 9,028 (1,413) 7,615 0.13 Corporate restructuring (b) 301 (71) 230 0.00 286 (67) 219 0.00 Acquisition-related 280 (11) 269 0.00 (68) 16 (52) (0.00) Medical Device Regulation expenses (c) 519 (123) 396 0.01 1,655 (391) 1,264 0.02 Other (d) — — — — 74 (17) 57 0.00 Other (Income) Expense Long-term debt costs (e) 1,414 (334) 1,080 0.02 1,414 (334) 1,080 0.02 Other non-operating loss (f) 254 (60) 194 0.00 260 (61) 199 0.00 Non-GAAP net income $ 87,226 $ (19,836) $ 67,390 $ 1.12 $ 73,176 $ (18,243) $ 54,933 $ 0.92 Diluted shares 60,379 59,919 Three Months Ended Three Months Ended September 30, 2026 September 30, 2025 Pre-Tax Tax Impact After-Tax Per Share Impact Pre-Tax Tax Impact After-Tax Per Share Impact

16 Reconciliation of GAAP Net Income to Non-GAAP Net Income (Unaudited; in thousands except per share amounts) Note: Certain per-share impacts may not sum to totals due to rounding. GAAP net income $ 160,645 $ (38,536) $ 122,109 $ 2.03 $ 119,877 $ (29,394) $ 90,483 $ 1.49 Non-GAAP adjustments: Cost of Sales Amortization of intangibles 55,941 (13,206) 42,735 0.71 55,798 (13,184) 42,614 0.70 Inventory mark-up related to acquisitions — — — — 250 (59) 191 0.00 Operating Expenses Contingent consideration (benefit) expense (70) (9) (79) (0.00) 1,198 29 1,227 0.02 Amortization of intangibles 7,490 (1,768) 5,722 0.10 7,497 (1,771) 5,726 0.09 Performance-based share-based compensation (a) 19,602 (1,727) 17,875 0.30 19,681 (2,344) 17,337 0.29 Corporate restructuring (b) 2,460 (581) 1,879 0.03 2,873 (678) 2,195 0.04 Acquisition-related 7,091 (916) 6,175 0.10 2,088 (2) 2,086 0.03 Medical Device Regulation expenses (c) 2,589 (611) 1,978 0.03 4,883 (1,153) 3,730 0.06 Other (d) — — — — 103 (24) 79 0.00 Other (Income) Expense Long-term debt costs (e) 9,305 (2,197) 7,108 0.12 4,242 (1,002) 3,240 0.05 Gain on disposal of business unit (12,502) 1,520 (10,982) (0.18) — — — — Other non-operating loss (f) 1,079 (267) 812 0.01 11 (61) (50) (0.00) Non-GAAP net income $ 253,630 $ (58,298) $ 195,332 $ 3.25 $ 218,501 $ (49,643) $ 168,858 $ 2.79 Diluted shares 60,134 60,604 Nine Months Ended Nine Months Ended September 30, 2026 September 30, 2025 Pre-Tax Tax Impact After-Tax Per Share Impact Pre-Tax Tax Impact After-Tax Per Share Impact

17 Reconciliation of GAAP Operating Income to Non-GAAP Operating Income (Unaudited; in thousands except percentages) Note: Certain percentages may not sum to totals due to rounding. Net Sales as Reported $ 416,244 $ 384,157 $ 1,216,964 $ 1,121,970 GAAP Operating Income 58,763 14.1 % 42,612 11.1 % 163,323 13.4 % 130,525 11.6 % Cost of Sales Amortization of intangibles 18,996 4.6 % 19,212 5.0 % 55,941 4.6 % 55,798 5.0 % Inventory mark-up related to acquisitions — — 183 0.0 % — — 250 0.0 % Operating Expenses Contingent consideration (benefit) expense (36) (0.0) % 32 0.0 % (70) (0.0) % 1,198 0.1 % Amortization of intangibles 2,540 0.6 % 2,560 0.7 % 7,490 0.6 % 7,497 0.7 % Performance-based share-based compensation (a) 7,173 1.7 % 9,028 2.4 % 19,602 1.6 % 19,681 1.8 % Corporate restructuring (b) 301 0.1 % 286 0.1 % 2,460 0.2 % 2,873 0.3 % Acquisition-related 280 0.1 % (68) (0.0) % 7,091 0.6 % 2,088 0.2 % Medical Device Regulation expenses (c) 519 0.1 % 1,655 0.4 % 2,589 0.2 % 4,883 0.4 % Other (d) — — 74 0.0 % — — 103 0.0 % Non-GAAP Operating Income $ 88,536 21.3 % $ 75,574 19.7 % $ 258,426 21.2 % $ 224,896 20.0 % Amounts % Sales Amounts % Sales Amounts % Sales Amounts % Sales Three Months Ended Three Months Ended Nine Months Ended Nine Months Ended September 30, 2026 September 30, 2025 September 30, 2026 September 30, 2025

18 Footnotes to Reconciliations of GAAP Net Income to Non-GAAP Net Income and GAAP Operating Income to Non-GAAP Operating Income a) Represents performance-based share-based compensation expense, including stock-settled and cash-settled awards. b) Includes employee termination benefits associated with activities related to corporate restructuring initiatives and costs to terminate certain distribution contracts from our Biolife Merger. c) Represents incremental expenses incurred to comply with the E.U. Medical Device Regulation. d) Represents costs to comply with Merit’s corporate integrity agreement with the U.S. Department of Justice. e) Represents costs associated with our Convertible Notes including the amortization of debt issuance costs and, for the nine-months ended September 2026, a one-time charge for additional interest incurred pursuant to Merit's obligation to remove restrictive legends. f) Includes equity method investment loss from equity investees.

19 Reconciliation of Reported Revenue to Constant Currency Revenue (Non-GAAP), and Constant Currency Revenue, Organic (Non-GAAP) (Unaudited; in thousands except percentages) (a) A non-GAAP financial measure. For a definition of this and other non-GAAP financial measures, see the section of this presentation entitled “Notes to Non-GAAP Financial Measures.” (b) On February 17, 2026, Merit consummated the DualCap Divestiture for consideration of $28 million, of which $25.5 million was paid to Merit at closing. % Change % Change Reported Revenue 8.4 % $ 416,244 $ 384,157 8.5 % $ 1,216,964 $ 1,121,970 Add: Impact of foreign exchange (1,082) — (12,005) — Constant Currency Revenue (a) 8.1 % $ 415,162 $ 384,157 7.4 % $ 1,204,959 $ 1,121,970 Less: Revenue from certain acquisitions — (2,634) (16,338) — Less: Revenue from divestitures (b) (5,228) — (1,644) (15,440) Constant Currency Revenue, Organic (a) 8.9 % $ 412,528 $ 378,929 7.3 % $ 1,186,977 $ 1,106,530 Three Months Ended Nine Months Ended September 30, September 30, 2026 2025 2026 2025

20 Reconciliation of GAAP Gross Margin to Non-GAAP Gross Margin (Unaudited; as a percentage of reported revenue) Note: Certain percentages may not sum to totals due to rounding. 2026 2025 2026 2025 Reported Gross Margin 48.2 % 48.5 % 49.4 % 48.4 % Add back impact of: Amortization of intangibles 4.6 % 5.0 % 4.6 % 5.0 % Inventory mark-up related to acquisitions — % 0.0 % — % 0.0 % Non-GAAP Gross Margin % 53.6 52.8 % 53.9 % 53.4 % September 30, Three Months Ended Nine Months Ended September 30,

21 Reconciliation of Reported Cash Flow from Operations to Free Cash Flow (Unaudited; in thousands) Reported Cash Flow from Operations $ 175,230 $ 198,861 Less: Capital Expenditures (57,252) (45,686) Free Cash Flow $ 129,544 $ 141,609 Nine Months Ended September 30, 2026 2025

Exhibit 99.3

Merit Medical Acquires Solo Pace, Inc., Expanding Its Cardiac Therapies Platform with Innovative TAVR Pacing Technology

●

Solo Pace, Inc. specializes in temporary pacing solutions and systems designed for transcatheter heart valve procedures, including transcatheter aortic valve replacement procedures.

SOUTH JORDAN, Utah, October 29, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced its acquisition of Solo Pace, Inc. (Solo Pace). Located in Minneapolis, Minnesota, Solo Pace manufactures temporary pacing technology designed to help physicians treat patients with aortic stenosis. Merit had previously invested in Solo Pace and on October 13, 2026, Merit acquired all remaining outstanding equity of Solo Pace for purchase consideration of approximately $45 million.

The acquisition expands Merit’s Cardiac Therapies platform with differentiated technologies, including SOLO PACE CONTROL™ and SOLO PACE FUSION™ systems, exclusively engineered for transcatheter aortic valve replacement (TAVR) and other transcatheter heart valve (THV) procedures. Prior to the acquisition, Merit served as the exclusive distributor of Solo Pace’s precision intraprocedural pacing technology. The acquisition builds on this existing commercial relationship and supports Merit’s strategy to expand its structural heart portfolio, with a focus on technologies designed to simplify procedural workflows and support physicians performing transcatheter heart valve procedures.

TAVR is a minimally invasive THV procedure that replaces the aortic valve in the heart. A treatment for aortic stenosis, or narrowing of the valve opening, TAVR is a rapidly growing procedure, with more than 100,000 performed annually in the United States alone.¹Temporary pacing is a critical component of TAVR procedures, supporting accurate valve deployment and helping physicians perform the procedure safely and efficiently.

SOLO PACE CONTROL and FUSION systems are designed to help physicians treat patients by simplifying pacing setup,² reducing workflow variability,^2,3 and standardizing pacing strategies for TAVR procedures.^2–4 The systems can help physicians minimize communication-related pacing errors^2–4 and decrease the risk of vascular complications.^2,4,5–7

SOLO PACE FUSION is a single-use, sterile kit designed for temporary intracardiac pacing for TAVR and other THV procedures. Combining guide wire functionality, left ventricular pacing, and patient grounding in one device, SOLO PACE FUSION is designed to provide stable, reliable temporary pacing throughout pacing setup and delivery.^2,8

Designed for use with the existing SOLO PACE CONTROL external pulse generator, SOLO PACE FUSION is engineered to improve procedural efficiency during TAVR procedures.⁸ In addition, it supports temporary pacing with operator-specific protocols, automated pace capture checks, sterile remote-control operation, and simple visual indicators.

“SOLO PACE CONTROL and FUSION systems have the potential to redefine pacing in transcatheter valve procedures,” said David V. Daniels, MD, Interventional Cardiologist and Founder of Solo Pace. “Seeing the technology embraced by physicians and having a meaningful impact on procedural efficiency has been incredibly gratifying. With Merit taking the lead, I’m excited for the difference the Solo Pace products can make in advancing patient care and market adoption.”

Solo Pace announced U.S. Food and Drug Administration (FDA) 510(k) clearance and commercial release of the SOLO PACE FUSION system on April 17, 2025, and March 31, 2026, respectively.

“This acquisition expands our Cardiac Therapies platform and further strengthens our position in the structural heart market,” said Martha G. Aronson, Merit’s President and Chief Executive Officer. “Through our exclusive distribution relationship, we have seen a favorable response from clinicians. That experience reinforces our confidence in the technology and the opportunity to support its next phase of growth. We look forward to leveraging our commercial, clinical, and physician education capabilities to expand adoption in the United States and, over time, bring these solutions to more physicians and patients worldwide.”

Learn more about SOLO PACE CONTROL and SOLO PACE FUSION.

1. Cleveland Clinic. 2025. “How and Why Volumes Matter In Aortic Valve Replacement.” Last modified January 22, 2025.

2. Data on file.

3. Blusztein et al. 2023. Struct Heart. doi: 10.1016/j.shj.2023.100213.

4. Berman et al. 2024. Struct Heart. doi: 10.1016/j.shj.2024.100306.

5. Faurie et al. 2019. JACC Cardiovasc Interv. doi: 10.1016/j.jcin.2019.09.029.

6. Regueiro et al. 2023. JACC Cardiovasc Interv. doi: 10.1016/j.jcin.2023.10.035.

7. Arnold et al. 2014. Circ Cardiovasc Interv. doi: 10.1161/CIRCINTERVENTIONS.114.001395.
8. Pasupati. “First-in-Human Experience with LV Guidewire Pacing.” TCT, October 2025.

FINANCIAL SUMMARY

On October 13, 2026, Merit paid purchase consideration of approximately $45 million to acquire all remaining outstanding equity of Solo Pace. Merit previously owned approximately 18% of Solo Pace pursuant to various agreements executed between January 2023 and December 2025 under which Merit paid a total of $5 million to acquire

shares of Solo Pace, an option to acquire all remaining outstanding equity of Solo Pace based on certain commercialization milestones, and exclusive rights to distribute the Solo Pace products upon commercialization.

From the acquisition effective date of October 13, 2026, through December 31, 2026, the acquisition is projected to be immaterial to Merit’s previously forecasted full-year 2026 total revenue, non-GAAP net income and non-GAAP earnings per share. The acquisition is expected to be immaterial to Merit’s previously forecasted full-year 2026 GAAP net income and GAAP earnings per share.

For the twelve months ending December 31, 2027, the acquisition is projected to be slightly accretive to non-GAAP net income and non-GAAP earnings per share, inclusive of approximately $1.5 million of lower interest income on cash balances used for the total purchase consideration and excluding approximately $3.2 million of non-cash and non-recurring transaction-related expenses. The acquisition is projected to be slightly dilutive to Merit’s GAAP net income and GAAP earnings per share in 2027 and accretive thereafter.

NON-GAAP FINANCIAL MEASURES

Merit generally does not provide guidance for GAAP reported financial measures (other than revenue) or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures (other than revenue) because Merit is unable to predict with reasonable certainty the financial impact of various items which could impact Merit’s future financial results, such as expenses attributable to acquisitions or other extraordinary transactions, non-cash expenses related to amortization or write-off of previously acquired tangible and intangible assets, certain employee termination benefits, performance-based stock compensation expenses, expenses resulting from non-ordinary course litigation or administrative proceedings and resulting settlements, governmental proceedings, and changes in governmental or industry regulations. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For the same reasons, Merit is unable to address the significance of the unavailable information, which could be material to future results. Specifically, Merit is not, without unreasonable effort, able to reliably predict the impact of these items, and Merit believes inclusion of a reconciliation of these forward-looking non-GAAP measures to their GAAP counterparts could be confusing to investors or cause undue reliance. Only information on the impacts to such measures from the proposed acquisition is included in this release. A reconciliation of the impacts on such financial measures to the impacts on their GAAP counterparts is not available without unreasonable effort.

ADVISORS

Parr Brown Gee & Loveless served as legal advisor to Merit in connection with the transaction.

ABOUT MERIT MEDICAL
Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves customers worldwide with a domestic and international sales force and clinical support team totaling approximately 900 individuals. Merit employs approximately 7,500 people worldwide.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

Statements proceeded or followed by, or that include the words, “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “intends,” “seeks,” “believes,” “estimates,” “projects,” “forecasts,” “potential,” “target,” “continue,” “upcoming,” “optimistic” or other forms of these words or similar words or expressions, or the negative thereof or other comparable terminology;

Statements that address Merit’s future operating performance or events or developments that Merit’s management expects or anticipates will occur, including, without limitation, any statements regarding Merit’s projected revenues, revenue growth or other financial measures, Merit’s plans and objectives for future operations, Merit’s proposed new products or services, the integration, development or commercialization of the business or any assets acquired from other parties, future economic conditions or performance, the implementation of, and results which may be achieved through, Merit’s Continued Growth Initiatives Program or other business optimization initiatives, and any statements of assumptions underlying any of the foregoing; and

Statements regarding Merit’s past performance, efforts, or results about which inferences or assumptions may be made, including statements proceeded or followed by the words "preliminary," "initial," "potential," "possible," "diligence," "industry-leading," "compliant," "indications," or "early feedback" or other forms of these words or similar words or expressions, or the negative thereof or other comparable terminology.

The forward-looking statements contained in this release are based on Merit management’s current expectations and assumptions regarding future events or outcomes. If underlying expectations or assumptions prove inaccurate, or risks or uncertainties materialize, actual results will likely differ, and could differ materially, from Merit’s expectations reflected in any forward-looking statements. Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results. Investors are cautioned not to unduly rely on any such forward-looking statements.

The following are some of the important risks and uncertainties that could cause Merit’s actual results to differ from Merit’s expectations in any forward-looking statements: risks and uncertainties associated with Merit’s acquisition of Solo Pace and SOLO PACE CONTROL and FUSION systems and related technology; risks and uncertainties associated with Merit’s integration of the Solo Pace business, assets and operations into its operations and its ability to achieve anticipated financial results, product development and other anticipated benefits of the acquisition; uncertainties as to whether Merit will achieve revenue or other financial performance consistent with its forecasts projected for the Solo Pace acquisition; risks and uncertainties regarding trade policies or related actions implemented by the United States or other countries, including existing, proposed, prospective or invalidated tariffs, duties or other measures; risks and uncertainties associated with Merit’s integration of businesses or assets acquired from third parties, including View Point Medical, Inc. in April 2026, the business and assets related to the C2 CryoBalloon™ device acquired from Pentax of America, Inc. in November 2025 and Biolife Delaware, L.L.C. in May 2025, and Merit’s ability to achieve the anticipated operating and financial results, product development and other anticipated benefits of such acquisitions; effects of Merit’s 3.00% Convertible Senior Notes due 2029 on Merit’s net income and earnings per share performance; disruptions in Merit’s supply chain, manufacturing or sterilization processes; U.S. and global political, economic, competitive, reimbursement and regulatory conditions; risks and uncertainties associated with Merit’s executive succession and leadership transition; modification or limitation of, or policies and procedures associated with, governmental or private insurance reimbursement policies; reduced availability of, and price increases associated with, components and other raw materials; increases in transportation expenses; risks relating to Merit’s potential inability to successfully manage growth through acquisitions generally, including the inability to effectively integrate acquired operations or products or commercialize technology developed internally or acquired through completed, proposed or future transactions; prospective financial obligations or other uncertainties associated with Merit’s divestiture of its DualCap® anti-microbial cap product line in February 2026; fluctuations in interest or foreign currency exchange rates and inflation; cybersecurity events; government scrutiny and regulation of the medical device industry; difficulties relating to development, testing and regulatory approval, clearance and maintenance of Merit’s products; the safety, efficacy and patient and physician adoption of Merit’s products; the ability to fully enroll and the outcomes of ongoing and future clinical trials and market studies relating to Merit’s products; litigation and other legal proceedings affecting Merit; the risk and possible effects of any failure to comply with U.S. and foreign laws and regulations; restrictions on Merit’s liquidity or business operations resulting from its debt agreements; infringement of Merit’s technology or the assertion that Merit’s technology infringes the rights of other parties; product recalls and product liability claims; potential for significant adverse changes in governing regulations;, changes in tax laws and regulations in the United States or other jurisdictions or exposure to additional tax liabilities which may adversely affect Merit’s effective tax rate; termination of relationships with Merit’s suppliers, or failure of such suppliers to perform; development of new products and technology that could render Merit’s existing or future products obsolete;

market acceptance of new products; failure to comply with applicable environmental laws; changes in key personnel; labor shortages and increases in labor costs; price and product competition; extreme weather events; and geopolitical events. For a further discussion of the risks and uncertainties that may affect Merit’s business, operations and financial condition, see Part I, Item 1A. “Risk Factors” in Merit’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (SEC), Part II, Item 1A, “Risk Factors” in Merit’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 filed with the SEC and Merit’s other filings with the SEC.

All subsequent forward-looking statements attributable to Merit or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results. Those estimates and all other forward-looking statements included in this release are made only as of the date of this release, and except as otherwise required by applicable law, Merit assumes no obligation to update or disclose revisions to estimates and all other forward-looking statements.

TRADEMARKS

Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc., its subsidiaries, or its licensors.

CONTACTS

PR/Media Inquiries
Sarah Comstock

Merit Medical
+1-801-432-2864 | sarah.comstock@merit.com

Investor Inquiries
Mike Piccinino, CFA, IRC

ICR Healthcare
+1-443-213-0509 | mike.piccinino@icrhealthcare.com

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

6 documents

Merit Medical Q3 revenue rises 8.4% to $416M

Rhea-AI Filing Summary

Positive

Negative

Insights

8-K Event Classification

Key Figures

Key Terms

Earnings Snapshot

FAQ

How did MMSI perform in the third quarter of 2026?

What is MMSI's updated 2026 financial guidance?

How did MMSI structure its Solo Pace acquisition, and what is the projected impact?

Filing Exhibits & Attachments

Press Releases

Other Documents

Keep reading

More on MMSI

Trending in the feed